Health
Deactivating gene could boost immunotherapy for head and neck cancer – Drug Target Review
Inhibiting the KDM4A enzyme slowed the growth of head and neck cancer in mouse models, also demonstrating promise to aid immunotherapy.
Posted: 24 March 2021 | Victoria Rees (Drug Target Review) | No comments yet
Inhibiting the KDM4A enzyme slowed the growth of head and neck cancer in mouse models, also demonstrating promise to aid immunotherapy.
By targeting an enzyme that plays a key role in head and neck cancer cells, researchers were able to significantly slow the growth and spread of tumours in mice and enhance the effectiveness of an immunotherapy to which these types of cancers often become resistant. The study was conducted…
-
General10 hours agoCampers evacuated, residents on alert as Moreton Island bushfire intensifies
-
Noosa News22 hours agoResilience features in Sunshine Coast Open House
-
Noosa News17 hours agoPerth Royal Show vendors upset by price hikes, say crowds are down in 2025
-
Business18 hours agoBell Potter names the best ASX shares to buy in October